Browsed by
Tag: presentation

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals Announces CTP-543 Alopecia Areata Data Selected for Late-Breaker Oral Presentation at 2020 EADV Virtual Congress

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present clinical data on CTP-543 for the treatment of alopecia areata as a late-breaker oral presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress. The meeting will be held virtually October 29-31, 2020. The oral presentation will highlight new data from an ongoing open label extension study evaluating long-term safety and treatment effects of CTP-543 in patients with moderate to severe alopecia areata.

The details of the presentation are as follows:

  • Title: Initial Results from a Long-Term, Open-Label Extension Study with CTP-543, an Oral Janus Kinase Inhibitor, in Patients with Moderate to Severe Alopecia Areata

  • Date and Time: Thursday, October 29, 2020, 3:00 – 3:15 pm Central European Time

  • Session: D1T03.3C: Late-Breaking News Session

  • Location: EADV Virtual Meeting. Registration is required to participate: https://eadvvirtualcongress.org/registration/

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration (FDA) has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata. The Company expects to begin Phase 3 evaluation of CTP-543 in the fourth quarter of 2020. Additional information on the upcoming trial is available on www.clinicaltrials.gov.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious

Read the rest
ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor …

ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor …

SOUTH SAN FRANCISCO and SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) — ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced a poster presentation and oral discussion at the upcoming 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held virtually October 24 – 25, 2020. The presentation will highlight preclinical data in prostate cancer cell lines that demonstrate the company’s glucocorticoid receptor (GR) antagonist, ORIC-101, reversing GR-mediated resistance to an androgen receptor (AR) degrader.

In the study, it was observed that upon treatment of prostate cancer cell lines with an AR degrader, GR mRNA and protein levels were significantly upregulated, similar to the GR upregulation seen after dosing with enzalutamide. This GR upregulation translated into GR activation that conferred resistance to the AR degrader, permitting prostate cancer cells to continue to grow. ORIC-101 was shown to completely reverse these effects and block tumor cell growth and androgen-regulated gene expression. These data demonstrate that GR may be a mechanism of resistance to AR degraders and that in vitro, ORIC-101 overcomes GR-driven resistance to AR degradation.

GR has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC-101 is currently in two separate Phase 1b trials of ORIC-101 in combination with Xtandi (enzalutamide) in metastatic prostate cancer and Abraxane (nab-paclitaxel) in advanced or metastatic solid tumors. ORIC expects to report interim data from one of the trials in the first half of 2021 and from the other trial in the second half of 2021.

Details of the poster presentation are as follows:

Title: ORIC-101 Overcomes GR-driven Resistance to AR Degradation in Castration-Resistant Prostate Cancer Models
Date: October 25, 2020; 2:30 p.m. CEST
Session: Poster Discussion Session
Topic: Approaches to Overcoming

Read the rest